Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Meiji Seika Enters Deal With U.S. Firm For Schizophrenia Drug

This article was originally published in PharmAsia News

Executive Summary

Meiji Seika Kaisha of Japan is joining with U.S. drug maker Acadia Pharmaceuticals to produce a biotech-based drug to treat schizophrenia. Meiji Seika has obtained development and marketing rights for the drug in Japan, China and 14 other nations in Asia. The schizophrenia drug is being prepared for trials in the United States. With its partnerships, the Japanese maker expects collaboration on early trials beginning by the middle of next year. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel